

PROVIDER QUICK POINTS

PROVIDER INFORMATION



June 12, 2024

Commercial Pharmacy Benefit Exclusion for Jesduvroq, Tofidence™, and Tyenne®

Effective **June 12, 2024**, the drugs listed in the table below will be excluded from pharmacy benefit coverage due to clinician-administered route of administration and may be available for medical benefit coverage for subscribers who are eligible.

Drug Names
JESDUVROQ (daprodustat) tablets
TOFIDENCE™ (tocilizumab-bavi) solution for intravenous (IV) infusion
TYENNE® (tocilizumab-aazg) solution for intravenous (IV) infusion

Products Impacted

These exclusions apply to commercial lines of business.

Questions?

Please contact provider services at **(651) 662-5200** or **1-800-262-0820**.